首页>投融资
Tryp Therapeutics
IPO后其他轮次
TRYP THERAPEUTICS INC is a clinical stage drug development company led by a management team with extensive drug development experience developing a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.In February 2022, Tryp Therapeutics Inc had announced a non-brokered private placement consists of 11,111,111 million units at a price of $0.18 per Unit, to raise gross proceeds of approximately $2.0 million.In February 2021, Tryp Therapeutics Inc had announced a non-brokered private placement of 3,333,333 million units at a price of $0.60 per Unit, to raise gross proceeds of approximately $2.0 million
基本信息
-
公司全称Tryp Therapeutics Inc
-
类型化合物药物研发商
-
产业领域研发制造服务、药品研发/制造
-
公司人数15人以下
-
地址c/o Pushor Mitchell LLP 301 - 1665 Ellis Street KELOWNA BRITISH COLUMBIA V1Y 2B3; CA; Telephone: +12507171840;
-
联系电话
-
邮箱Investors@tryptherapeutics.com
-
成立时间2019-01-01
投融资
-
2023-11-20IPO后其他轮次210.2万美元未透露
-
2023-04-27IPO后其他轮次156.98万美元未透露
-
2021-02-05IPO后其他轮次200万美元未透露
-
2020-12-17上市500万美元未透露
- 加载更多
相关投融资企业
B轮
PhoreMost Ltd is a biopharmaceutical company developing therapeutics for cancer and other difficult diseases. The company is managed by the founder of the University of Cambridge spin-off Horizon Discovery.In March 2021, XtalPi invested in the Series B financing of PhoreMost Ltd.In March 2021, PhoreMost Ltd announced it has completed an oversubscribed £33m ($46m) Series B investment round,.In March 2021, o2h Ventures invested into PhoreMost Ltd.In May 2018, the company completed a GBP 11 million ($14.92 million) series-A investment round.In April 2015, the company raised GBP 2.5 million ($3.26 million) in a seed-funding
A轮
Superluminal Medicines是一家生成生物学和化学公司,该公司正在开发一种差异化的管道,并彻底改变药物生产的速度和准确性。该公司的平台利用深度生物学和化学专业知识、机器学习和专有大数据基础设施的全面结合,以前所未有的速度创建候选化合物。该平台的 "预测-设计-测试 "架构能够准确地模拟蛋白质形状,并设计出高选择性的化合物,以针对精确的结构变化达到治疗效果。其发现引擎由业界领先的药代动力学和毒理学计算机预测能力提供动力。
B轮
OrsoBio is a clinical-stage biopharmaceutical company, incubated by Samsara BioCapital, focused on developing therapies for the potential treatment of severe metabolic disorders, including diabetes, severe dyslipidemias and lipodystrophies